October Events: Regional Conference on Mesothelioma in Chicago

Chicago brochure coverThe 2014 Chicago Regional Conference on Malignant Mesothelioma is a one-day event geared to patients and family members, covering a variety of topics related to mesothelioma and presented by local and regional area experts. The conference is a collaborative effort between the Mesothelioma Applied Research Foundation and The University of Chicago Medicine.

The conference is geared towards patients (newly diagnosed or those looking to learn about second-line and beyond treatment options), caregivers, family members, general health practitioners, and anyone wishing to learn more about mesothelioma. Topics of discussion include imaging, genetics, surgery, chemotherapy, novel treatments, stem cells, immunotherapy, and resources for patients and families.

The location of the conference is the Palmer House Hilton at 17 E Monroe Street, Chicago, IL 60603. The event will begin at 9:30am and commence with a cocktail reception at 5pm. The registration cost is $25, and includes breakfast and lunch.

More information and registration is available at curemeso.org/chicago.

The Meso Foundation is also the host of an annual symposium, taking place in March of every year in the Washington, DC area, and another regional conference in Philadelphia in September.

More Promising Mesothelioma Clinical Trials than Ever Before

Doctor speaking to patientDuring the July 2014 board meeting of the Mesothelioma Applied Research Foundation, mesothelioma expert and executive director of the Meso Foundation, Mary Hesdorffer, APRN, stated that mesothelioma patients today have more promising clinical trials to choose from than ever before.

In her talk, she mentioned several trials that have been reporting increased survival and response rates. Some include novel radiation treatments, while the focus of others is within the field of immunotherapy. One trial, in particular, is looking very promising with a 69% durable response in a small group of patients. Ms. Hesdorffer stated that a new, larger trial currently underway is looking to confirm these results.

“A clinical trial is a unique opportunity for a patient to try something new and innovative that could have a very positive impact on the patient’s disease,” said Ms. Hesdorffer. “Having options is an important step forward in a disease that merely a decade ago was seen as hopeless,” she added.

Ms. Hesdorffer provides free consultations about clinical trials, as well as other issues pertaining to mesothelioma, as part of the Mesothelioma Applied Research Foundation’s patient services.

“While healthcare providers aren’t able to review all clinical trial options with their patients due to time constrains, at the Meso Foundation it is our job to spend the necessary time to go through all viable options while taking into consideration insurance coverage, stage of disease, histology and readiness to participate in a clinical trial,” added Ms. Hesdorffer.

Mary Hesdorffer, MS, APRN-BC, is a nurse practitioner with over 16 years of experience in mesothelioma treatment. She is an expert in clinical trials for mesothelioma and her work has been published in a variety of scientific journals.

The Mesothelioma Applied Research Foundation has recently released a downloadable brochure about mesothelioma clinical trials, which can also be requested by mail, and lists all mesothelioma clinical trials on its website.

Focus on Mesothelioma in Pharmaceutical Company Investor Meeting

Mary at Verastem, Inc.On July 10, during the research and development portion of the Verastem, Inc.’s investor meeting, Mary Hesdorffer, APRN, the executive director of the Mesothelioma Applied Research Foundation, was a featured speaker. In her talk, Ms. Hesdorffer focused on the need for clinical trials to increase the number of viable therapeutic options for mesothelioma.

According to their website, Verastem, Inc. is a “clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis.”

“When we look at the mesothelioma patient, we have one regimen, pemetrexed and cisplatin, approved in 2003,” said Ms. Hesdorffer. “40% of the patients were found to respond to the treatment, but unfortunately, it’s not a durable response,” she added.

Ms. Hesdorffer continued her speech by focusing on the need to do more for mesothelioma patients to increase time to relapse or even to delay relapse indefinitely. She argues that keeping patients healthier for longer periods of time, improving their quality of life, and keeping them in good shape, positions them as good candidates for major breakthroughs that might develop in the future.

Mary Hesdorffer, MS, APRN-BC, is an expert nurse practitioner with over 16 years of experience in mesothelioma treatment. She is an expert in clinical trials for mesothelioma and her work has been published in a variety of scientific journals. She has spoken about mesothelioma, clinical trials, and the dire need for life-saving mesothelioma treatments to the US Congress and the UK Parliament, as well as many seminars and conferences, including the World Conference on Lung Cancer, where in 2015 she will be the program chair of the Nursing and Allied Health section.

For more information on mesothelioma clinical trials, and to download the Meso Foundation’s free clinical trials booklet, visit curemeso.org.

September Events: Regional Conference on Mesothelioma in Philadelphia

2013 International Symposium on Malignant MesotheliomaA mesothelioma conference presented by the Mesothelioma Applied Research Foundation and Penn’s Abramson Cancer Center, will be held in Philadelphia on September 26, 2014. The conference will bring together area experts in the field of mesothelioma. September 26 marks the National Mesothelioma Awareness Day.

The conference is open to the public, and specifically aimed at mesothelioma patients, family members, caregivers, healthcare professionals, and those who have been exposed to asbestos.

The conference will take place on Friday, September 26, 2014 at The HUB, Cira Centre at the Penn’s Abramson Cancer Center, located at 2929 Arch Street, Philadelphia, PA 19104. To register for the conference, visit OncoLink.org/Conference/Mesothelioma or call 800.789.PENN (7366) and press 2.

The conference is co-chaired by Mary Hesdorffer, CRNP, of the Meso Foundation, Joseph Friedberg, MD, of the Penn’s Abramson Cancer Center, and Daniel Sterman, MD, of the Penn’s Abramson Cancer Center. Among topics of discussion at the conference will be clinical trial participation, latest advances in peritoneal and pleural mesothelioma, palliative care, early detection, genetics, coping with mesothelioma, and survivorship.

Speakers include:
Mary Hesdorffer, CRNP, Mesothelioma Applied Research Foundation
Joseph Friedberg, MD, Penn’s Abramson Cancer Center
Chi Dang, MD, PhD, Penn’s Abramson Cancer Center
Julie Brahmer, MD, Johns Hopkins University
Richard Alexander, MD, University of Maryland
Lee Krug, MD, Memorial Sloan Kettering Cancer Center
Andreas Rimner, MD, Memorial Sloan Kettering Cancer Center
Daniel Sterman, MD, Penn’s Abramson Cancer Center
Suzanne Walker, CRNP, MSN, AOCN, BC, Penn’s Abramson Cancer Center
Anil Vachani, MD, Penn’s Abramson Cancer Center
Joseph Testa, PhD, Fox Chase Cancer Center
Eleanor Anderson, MD, Penn’s Abramson Cancer Center

For more information, visit curemeso.org.

BREAKING NEWS: Mesothelioma Trial Results Show No Improvement in Overall Survival

Researcher

In the July 5, 2014 edition of Lung Cancer, Dr. Lee Krug of Memorial Sloan Kettering Cancer Center, who was the lead investigator of the CBP501 trial, reported that the trial was found not to improve overall survival in patients with malignant mesothelioma.

CBP 501 is a drug in that interrupts DNA repair of transformed cells. It was thought to add synergy to the combination of our first line therapy.

Cisplatin/pemetrexed coupled with a placebo or CBP501, at first glance, appeared to hold promise, having met their endpoint of progression-free survival at 4 months. However, in further evaluation, it was found not to increase overall survival or response rate.

Though we are disappointed to learn of these results, the science from this study nonetheless adds to our knowledge of this disease. We are grateful to all volunteers who participated, because only through a clinical trial are we able to learn what works and what doesn’t.

Read the abstract here. http://www.lungcancerjournal.info/article/S0169-5002(14)00266-9/abstract